Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Welcome to Pharm-Olam Insights

Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID-19 and its effect on the clinical landscape.

Natural History - Case Study: Ultra Rare Disease in Subjects Aged 3 Years and Younger

Pharm-Olam is a clinical research organization (CRO) with global reach and deep expertise in rare disease research. Our...

(3 minute read)

Tags: Rare & Orphan Disease

Complexities of Combining Adults into Protocol with Pediatrics and Adolescents

Conducting Phase I studies is always complex. At this stage in clinical research, you are examining the tolerability of the...

(1 minute read)

Tags: Pharm-Olam Insights, Allergy & Immunology

How Rave CSA Supports Remote Monitoring in COVID-19

In a world with COVID-19, remote monitoring is now essential to effectively monitor studies. Sponsors and CROs are either...

(2 minute read)

Tags: Pharm-Olam Insights, COVID-19

Conducting Clinical Trials in South Africa: A Revitalized Environment

South Africa was once a commonly considered country for inclusion in clinical research, but its popularity caused bottlenecks...

(4 minute read)

Tags: Pharm-Olam Insights, Global Coverage

DISCOVER 360: Pharm-Olam’s Comprehensive Approach to Site Selection

Site Selection is arguably the most critical element to study success. You can have a “perfectly” designed protocol, an...

(6 minute read)

Tags: Pharm-Olam Insights

Allergy Immunotherapy in Adult and Pediatric Subjects with Peanut Allergy

Pharm-Olam is a mid-sized, global CRO that provides clinical research solutions with a specialization in allergy and autoimmune

(1 minute read)

Tags: Allergy & Immunology

Understanding the New Asthma Guidelines

In the midst of the COVID-19 pandemic, breathing issues and respiratory conditions are significant concerns. According to the ...

(4 minute read)

Tags: Pharm-Olam Insights, Allergy & Immunology, Asthma

Multicenter Phase III Study Efficacy of mAb Treatment for Ventilator-Associated Pneumonia (VAP)

Pharm-Olam was hired to support a Phase 3 study of a monoclonal antibody (mAb) and its impact on patients with...

(0 minute read)

Tags: Infectious Disease & Vaccines

Join other Clinical Development experts to receive the latest industry news, trends and insights.

Subscribe to our blog and we'll give you our GDPR Controller & Processor Checklist.